My bookmarksSign up free

Commission Decision of 22 December 2006 concerning a financial contribution by the Community for the implementation of an epidemiological survey and bluetongue surveillance measures in the context of the emergency measures taken to combat this disease in Belgium, Germany, France, Luxembourg and the Netherlands in 2006 and 2007 (notified under document number C(2006) 6968)

Commission Decision of 22 December 2006 concerning a financial contribution by the Community for the implementation of an epidemiological survey and bluetongue surveillance measures in the context of the emergency measures taken to combat this disease in Belgium, Germany, France, Luxembourg and the Netherlands in 2006 and 2007 (notified under document number C(2006) 6968)

Decision · 5 articles

Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗

Granting of a financial contribution from the Community to Belgium, Germany, France, Luxembourg and the Netherlands

Article 1

1.   In the context of the emergency measures taken to combat bluetongue in 2006 and 2007, Belgium, Germany, France, Luxembourg and the Netherlands shall be entitled to a financial contribution from the Community amounting to 50 % of the expenditure incurred for the costs of the laboratory tests for serological and virological surveillance and for the costs of entomological surveillance, including the purchase of traps. 2.   The maximum amounts of the costs to be reimbursed to Belgium, Germany, France, Luxembourg and the Netherlands for an ELISA test for serological surveillance referred to in paragraph 1 shall not exceed EUR 2,5 per test carried out. 3.   The financial contribution from the Community shall exclude value added tax.

Payment arrangements

Article 2

Subject to the results of any on-the-spot checks carried out in accordance with Article 9(1) of Decision 90/424/EEC, a first tranche payment as part of the Community financial contribution provided for Article 1 shall be paid as follows: (a) EUR 300 000 to Belgium; (b) EUR 2 200 000 to Germany; (c) EUR 100 000 to France; (d) EUR 25 000 to Luxembourg; (e) EUR 165 000 to the Netherlands. That payment shall be made on the basis of supporting documents submitted by Belgium, Germany, France, Luxembourg and the Netherlands relating to the laboratory tests for serological, virological and entomological surveillance and for the purchase of traps, referred in Article 1(1).

Payment conditions and supporting documents

Article 3

1.   The financial contribution from the Community as referred to in Article 1 shall be paid on the basis of: (a) forwarding an intermediate technical report on the technical execution of the surveillance measures including the results attained during the period from 15 August 2006 to 31 March 2007; (b) forwarding an intermediate financial report, in computerised form in accordance with the Annex, on the costs paid by the Member State during the period from 15 August 2006 to 31 March 2007; (c) forwarding a final technical report on the technical execution of the surveillance measures including the results attained during the period from 15 August 2006 to 31 December 2007; (d) forwarding a final financial report, in computerised form in accordance with the Annex, on the costs paid by the Member State during the period from 15 August 2006 to 31 December 2007; (e) the results of any on-the-spot checks carried out in accordance with Article 9(1) of Decision 90/424/EEC. The documents referred in points (a) to (d) shall be made available for on-the-spot checks referred in point (e) carried out by the Commission. 2.   The intermediate technical report and the intermediate financial report referred to in paragraph 1 (a) and (b) shall be submitted by 31 May 2007 at the latest. If that time limit is not observed, the financial contribution from the Community shall be reduced by 25 % for every calendar month of delay. 3.   The final technical report and the final financial report referred to in paragraph 1 (c) and (d) must be submitted by 31 May 2008 at the latest. If that time limit is not observed, the financial contribution from the Community shall be reduced by 25 % for every calendar month of delay.

Addressees

Article 4

This Decision is addressed to the Kingdom of Belgium, the Federal Republic of Germany, the French Republic, the Grand Duchy of Luxembourg and the Kingdom of the Netherlands.

Supplementary provisions

ANNEXSupplementary provisions

ANNEX Data referred to in Article 3(1)(b) and (d) Costs incurred Nature of action Number Amount (not including VAT) ELISA Tests     PCR Tests     Other virological tests     Entomological tests     Traps     Total

Other acts of the same type
Commission Implementing Decision (EU) 2025/945 of 22 May 2025 postponing the expiry date of the approval of nonanoic acid for use in biocidal products of product-type 2 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the CouncilCommission Implementing Decision (EU) 2025/946 of 22 May 2025 postponing the expiry date of the approval of octanoic acid for use in biocidal products of product-type 4 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the CouncilCommission Implementing Decision (EU) 2025/947 of 22 May 2025 postponing the expiry date of the approval of iodine for use in biocidal products of product-type 3 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the CouncilCommission Implementing Decision (EU) 2025/949 of 22 May 2025 postponing the expiry date of the approval of decanoic acid for use in biocidal products of product-type 4 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the CouncilCommission Implementing Decision (EU) 2025/950 of 22 May 2025 postponing the expiry date of the approval of 1R-trans phenothrin for use in biocidal products of product-type 18 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the CouncilCommission Implementing Decision (EU) 2025/951 of 22 May 2025 postponing the expiry date of the approval of polyvinylpyrrolidone iodine for use in biocidal products of product-types 1 and 3 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the CouncilCommission Implementing Decision (EU) 2025/952 of 22 May 2025 postponing the expiry date of the approval of S-methoprene for use in biocidal products of product-type 18 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the CouncilCommission Implementing Decision (EU) 2025/970 of 22 May 2025 postponing the expiry date of the approval of IPBC for use in biocidal products of product-type 8 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the CouncilCommission Implementing Decision (EU) 2025/998 of 22 May 2025 postponing the expiry date of the approval of bis(N-cyclohexyl-diazenium-dioxy)-copper (Cu-HDO) for use in biocidal products of product-type 8 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the CouncilCommission Implementing Decision (EU) 2025/1083 of 22 May 2025 amending Implementing Decision (EU) 2024/2207 concerning certain emergency measures relating to sheep pox and goat pox in Greece (notified under document C(2025) 3430)Commission Implementing Decision (EU) 2025/1089 of 22 May 2025 amending the Annex to Implementing Decision (EU) 2023/2447 concerning emergency measures in relation to outbreaks of highly pathogenic avian influenza in certain Member States (notified under document C(2025) 3429)Council Decision (Euratom) 2025/1134 of 22 May 2025 on the adoption of the 2024-2027 high flux reactor supplementary research programme at Petten to be implemented by the Joint Research Centre for the European Atomic Energy Community

Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.

What to look at next